Business Context and Reporting Period
This Form 8-K Current Report from Modular Medical, Inc. (MODD) covers events occurring on January 23, 2026. The filing documents the results of the Company's fiscal 2026 annual meeting of shareholders and the subsequent filing of a charter amendment with the State of Nevada.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Corporate Actions
The following material changes were approved by shareholders and executed on January 23, 2026:
- Authorized Share Increase: The Company increased its authorized common stock from 100,000,000 to 250,000,000 shares via a Certificate of Amendment.
- Reverse Stock Split Authorization: Shareholders approved an amendment granting the Board of Directors the discretion to effect a reverse stock split within a specified range at any time within one year of the meeting, without further shareholder approval.
- Equity Plan Expansion: The 2017 Equity Incentive Plan was amended to increase the number of shares reserved for issuance by 3,000,000 shares.
- Director Elections: All eight director nominees (Duane DeSisto, Paul DiPerna, Steven Felsher, Morgan Frank, Jeffrey Goldberg, Philip Sheibley, Carmen Volkart, and Ellen O'Connor Vos) were elected.
- Auditor Ratification: Farber Hass Hurley LLP was ratified as the independent registered public accounting firm for the fiscal year ending March 31, 2026.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of specific risks and contingencies beyond the standard disclosures related to the charter amendments. The primary operational implication is the Board's new authority to execute a reverse stock split, which may impact share price and liquidity depending on future market conditions.
Investor Verification Checklist
- Verify the specific ratio and timing of the reverse stock split, as the Board has discretion to determine these details within the next year.
- Review the definitive proxy statement filed on January 8, 2026, for detailed rationale behind the equity plan expansion and director elections.
- Monitor future filings for the actual execution of the reverse stock split and its impact on the number of outstanding shares.
- Confirm the impact of the increased authorized share count on potential future dilution or capital raising activities.